Announcement of Availability for DSP-5336
February 27, 2025
The Cancer Therapy Evaluation Program (CTEP) is accepting Letters of Intent (LOIs) to conduct clinical studies using DSP-5336, an oral menin inhibitor, which is being developed by CTEP as an anticancer agent in collaboration with Sumitomo Pharma Oncology, Inc. CTEP will also consider requests to supply DSP-5336 for nonclinical studies. All clinical and nonclinical researchers possessing an interest in working with the agent are welcome to apply. Proposals for clinical trials should be supported by a strong rationale and robust preclinical data (see “Components of a Competitive Letter of Intent” at http://ctep.cancer.gov/protocolDevelopment/lois_concepts.htm).
All proposals approved by CTEP will be sent to the industry collaborator for a commitment to supply drug for the study.
If you are a HCC Investigator interested in submitting an LOI using sacituzumab govitecan through the ETCTN, please contact Dr. Geoffrey Shapiro (geoffrey_shapiro@dfci.harvard.edu).
Questions may be addressed to Dr. Steven Gore (steven.gore@nih.gov) Medical Officer, Investigational Drug Branch, CTEP, please CC Dr. Geoffrey Shapiro (geoffrey_shapiro@dfci.harvard.edu).